VistaGen Therapeutics
VTGN
17 hedge funds and large institutions have $3.8M invested in VistaGen Therapeutics in 2018 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 7 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
18% more capital invested
Capital invested by funds: $3.23M → $3.8M (+$569K)
0.01% less ownership
Funds ownership: 0.35% → 0.34% (-0.01%)
23% less funds holding
Funds holding: 22 → 17 (-5)
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
Top Buyers
VTGN Hedge Fund Activity: Q3 2018 in Review
17 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q3 2018, worth a combined $3.8M — up 18% from $3.23M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of VTGN and 2 opened new positions — a net loss of 5 holders — while 2 trimmed existing stakes and 3 added.
The largest buyer was Sphera Funds Management, adding an estimated $408K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $99K sold.
- 17 institutional investors held VistaGen Therapeutics (VTGN) as of Q3 2018, down from 22 in Q2 2018.
- Funds reported $3.8M of VistaGen Therapeutics stock for Q3 2018, up 18% quarter-over-quarter.
- 2 funds opened new VistaGen Therapeutics positions in Q3 2018 and 7 closed out, a net change of -5 holders.
- The largest VistaGen Therapeutics buyer in Q3 2018 was Sphera Funds Management, an estimated $408K added.
- The largest VistaGen Therapeutics seller in Q3 2018 was Susquehanna International Group, an estimated $99K sold.
Based on aggregated 13F filings for Q3 2018.